Bristol-Myers Squibb Cruiserath Biologics T/A Swords Laboratories And Swords Laboratories: [O'Hanrahan Gallogly] / [Hayes McGrath Solicitors], 36) 2019/05243 Eduard Ciuchi – V – Motor Insurers' Bureau ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

Importantly, Bristol-Myers Squibb Company (NYSE:BMY) does carry debt. But the real question is whether this debt is making the company risky. Debt and other liabilities become risky for a business ...

Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenefy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...

Valued at a market cap of $113.1 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company focused on developing innovative treatments for serious diseases ...